In the Wake of the AFFIRM Trial: What We Still Don't Know About the Management of Atrial Fibrillation and Where We Need to Go

Author： Wyse D.G.  

Publisher： Springer Publishing Company

ISSN： 1385-2264

Source： Cardiac Electrophysiology Review, Vol.7, Iss.2, 2003-01, pp. : 130-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The worldwide social burden of atrial fibrillation: What should be done and where do we go?

By Santini Massimo   Ricci Renato  

Journal of Interventional Cardiac Electrophysiology, Vol. 17, Iss. 3, 2006-12 ,pp. : 183-188

Springer Publishing Company

Access to resources Recommend Favorite

Postoperative Atrial Fibrillation - What Do We Really Know?

By  

Current Vascular Pharmacology, Vol. 8, Iss. 4, 2010-07 ,pp. : 553-572

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Mllerian hormone (AMH): what do we still need to know?

By La Marca A.   Broekmans F.J.   Volpe A.   Fauser B.C.   Macklon N.S.  

Human Reproduction, Vol. 24, Iss. 9, 2009-09 ,pp. : 2264-2275

Oxford University Press

Access to resources Recommend Favorite

Primary Fibrosarcoma of the Liver: We Don’t Know Much

By  

Case Reports in Gastroenterology, Vol. 2, Iss. 3, 2008-11 ,pp. : 384-389

Karger

Access to resources Recommend Favorite

AFFIRM and RACE Trials: Implications for the Management of Atrial Fibrillation

By Blackshear J.L.  

Cardiac Electrophysiology Review, Vol. 7, Iss. 4, 2003-12 ,pp. : 366-369

Springer Publishing Company

Access to resources Recommend Favorite